
COMMENTARY

Importance of counseling and patient selection in treatment of male stress incontinence

David E. Rapp, MD

Department of Urology, University of Virginia, Charlottesville, Virginia, USA

Referring to the article published on pp. 9121-9125 in this issue

RAPP DE. Importance of counseling and patient selection in treatment of male stress incontinence. *Can J Urol* 2017;24(6):9126.

Utilizing device purchasing data as a surrogate, the authors report AdVance male sling (AS) and artificial urinary sphincter (AUS) utilization trends from 2007-2015. Accordingly, following a surge in AS utilization coinciding with market introduction, AS utilization relative to AUS has more recently decreased. The authors suggest that AS overutilization may have been seen following its introduction in 2007, with a trend toward AUS use being more recently observed in conjunction with further understanding of optimal patient selection criteria for AS.¹

Indeed, patient selection when considering the surgical treatment of male stress urinary incontinence (SUI) is often complex. Early reports following AS introduction demonstrated efficacy and safety in a general patient population.² Given its minimally invasive quality, AS was not surprisingly popularized as a generalized treatment option for male SUI. With experience, however, it has become clear that patient selection is important to optimize outcomes following AS.

Foremost, numerous investigations demonstrate that patients with a history of pelvic radiation are suboptimal candidates for AS.^{3,4} Further, multiple studies demonstrate AS to be more efficacious in patients with mild to moderate urinary incontinence, suggesting that AUS is preferable in patients with more significant SUI.⁵ Finally, additional clinical findings such as detrusor overactivity and detrusor hypocontractility may be associated with poor outcomes.⁶ The importance of patient selection is highlighted by Sturm and colleagues, who demonstrated superior outcomes following AS when comparing "ideal" and "nonideal" patients based on selection criteria described above.⁷

Nonetheless, there are several characteristics that make AS attractive to patients even though they may not be ideal candidates. Foremost, AS is a more minimally invasive option that does not require dynamic activation during voiding. AS is also associated with

a lower complication rate.⁸ Further, AUS placement is feasible after failed AS and even demonstrates similar outcomes to primary AUS.⁹ This data is notable because, knowing that AUS is a viable secondary option, patients may choose AS even when counseled that they are suboptimal candidates. Anecdotally, I have found that when considering their surgical options, patients often ask whether AUS is possible in the event of AS failure and that additional factors as described above are often as important as SUI cure rate.

Combined, these data highlight the importance of patient education and the role physician counseling may have on treatment choice for male SUI. To provide optimal counseling, it is important that physicians are not only well informed about clinical outcomes but also patient preferences that also influence decision making. It will be interesting to follow comparative utilization of AS and AUS as I suspect many of these factors will continue to influence utilization trends moving forward. □

References

1. Pusateri CR, Zuckerman JM. AdVance sling use decreasing relative to artificial urinary sphincters. *Can J Urol* 2017;24(6):9121-9125.
2. Bauer RM, Soljanik I, Fullhase C et al. Results of the AdVance transobturator male sling after radical prostatectomy and adjuvant radiotherapy. *Urology* 2011;77(2):474-479.
3. Comiter CV, Dobberfuhr AD. The artificial urinary sphincter and male sling for postprostatectomy incontinence: Which patient should get which procedure? *Investig Clin Urol* 2016;57(1):3-13.
4. Habashy D, Losco G, Tse V et al. Mid-term outcomes of a male retro-urethral, transobturator synthetic sling for treatment of post-prostatectomy incontinence: Impact of radiotherapy and storage dysfunction. *Neurourol Urodyn* 2017;36(4):1147-1150.
5. Siegler N, Droupy S, Costa P. Sub-urethral sling AdVance midterm results: patient selection and predictors of success. *Prog Urol* 2013; 23(12):986-993.
6. Chung AS, Suarez OA, McCammon KA. AdVance male sling. *Transl Androl Urol* 2017;6(4):674-681.
7. Sturm RM, Guralnick ML, Stone AR et al. Comparison of clinical outcomes between "ideal" and "nonideal" transobturator male sling patients for treatment of postprostatectomy incontinence. *Urology* 2014;83(5):1186-1188.
8. Alwaal A, Harris CR, Awad MA et al. Comparison of complication rates related to male urethral slings and artificial urinary sphincters for urinary incontinence: national multi-institutional analysis of ACS-NSQIP database. *Int Urol Nephrol* 2016;48(10):1571-1576.
9. Lentz AC, Peterson AC, Webster GD. Outcomes following artificial sphincter implantation after prior unsuccessful male sling. *J Urol* 2012;187(6):2149-2153.

Address correspondence to Dr. David E. Rapp, 5829 Ascot Glen Drive, Glen Allen, VA 23059 USA